2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2017
Role of axillary node dissection after mastectomy with positive sentinel nodes.
Park T, Thomas S, Greenup R, Hwang E. Role of axillary node dissection after mastectomy with positive sentinel nodes. Journal Of Clinical Oncology 2017, 35: 554-554. DOI: 10.1200/jco.2017.35.15_suppl.554.Peer-Reviewed Original ResearchAxillary lymph node dissectionPositive sentinel nodesAdjuvant radiationNode dissectionSentinel nodesTumor sizeRadiation treatmentComparable overall survivalLymph node dissectionMedian tumor sizeNational Cancer DatabaseStage IV diseaseAxillary node dissectionBreast conservation therapyHazard of deathAxillary lymphadenectomyPositive SLNZ11 trialCause mortalityEndocrine therapyNeoadjuvant chemotherapyPositive nodesNegative patientsOverall survivalSentinel lymphTemporal associations between prognostic indicators and overall survival after breast cancer.
Plichta J, Thomas S, Fayanju O, Rosenberger L, Park T, Hyslop T, Greenup R, Hwang E. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal Of Clinical Oncology 2017, 35: e18144-e18144. DOI: 10.1200/jco.2017.35.15_suppl.e18144.Peer-Reviewed Original ResearchOverall survivalReduced overall survivalEndocrine therapyBreast cancerNon-metastatic invasive breast cancerAssociation of OSHormone receptorsTreatment factorsInvasive breast cancerLong-term outcomesInvasive ductal carcinomaMultivariate survival analysisUnderwent lumpectomyTerm outcomesDuctal carcinomaPrognostic indicatorMultiple time pointsBreast oncologistsSurvival analysisChemotherapyTime pointsTumorsCT/Temporal associationSurvival